Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kitasato Univ. Creates KCRC to Centrally Control 105 Beds for Clinical Studies
May 5, 2008
- Nippon Shinyaku Licenses PAH Treatment to Actelion
May 5, 2008
- Council Proposes Introduction of "Emergency Budgets for National Projects" in FY2009
May 5, 2008
- Astellas Licenses BACE Inhibitors from CoMentis
May 5, 2008
- R&D NEWS IN BRIEF
May 5, 2008
- Kyorin Licenses Flutiform from SkyePharma
May 5, 2008
- Will Generics Take Off? (2)
May 5, 2008
- Kyowa Hakko Licenses Antibody for Cancer from Arana of Australia
May 5, 2008
- A Saisei-kai Hospital Decides Not to Use Generics as a Rule
May 5, 2008
- DSP to Copromote Lonasen with Yoshitomi to Quickly Develop Market
May 5, 2008
- President Hatori Shows Confidence in Vigorous Growth of SSP from FY2009
May 5, 2008
- More APIs, Intermediates to Become Duty-Free
May 5, 2008
- SELF-MEDICATION NEWS IN BRIEF
May 5, 2008
- Chugai Revises Business Forecast Upward for 2008 due to Lower-than-expected NHI Price Revisions
May 5, 2008
- GENERICS NEWS IN BRIEF
May 5, 2008
- New JPMA President from Daiichi Sankyo?
May 5, 2008
- Carotid Artery Stenting Improves QOL: J&J Seminar
May 5, 2008
- Pharmacovigilance Enhanced under PDUFA IV: Seminar
April 28, 2008
- Pre-Pandemic Vaccination of Healthcare Providers Approved
April 28, 2008
- NEW PRODUCTS／DS Pharma Biomedical to Launch Serum-Free Medium
April 28, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…